Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

IN THE OPEN LABEL (OL) STUDY, AFTER 6-MONTHS OF DAILY NOMLABOFUSP ADMINISTRATION, 100% OF PARTICIPANTS (N = 10) ACHIEVED SKIN FXN LEVELS SIMILAR TO ASYMPTOMATIC CARRIERS CONSISTENT DIRECTIONAL IMPROVEMENT ACROSS MFARS, FARS-ADL, 9-HPT AND MFIS AFTER 1-YEAR IN OL STUDY REINFORCES THE POTENTIAL OF NOMLABOFUSP TO ALTER FA'S DISEASE COURSE RELATIVE TO A WORSENING IN A FACOMS NATURAL HISTORY STUDY REFERENCE POPULATION OF 39 PARTICIPANTS IN OL STUDY (AND OF 65 TOTAL PARTICIPANTS WHO RECEIVED AT LEAST 1 DOSE IN ALL NOMLABOFUSP STUDIES), 7 EXPERIENCED ANAPHYLAXIS IN THE FIRST 6 WEEKS OF DOSING AND RETURNED TO USUAL STATE OF HEALTH AFTER STANDARD TREATMENT; EXCLUDING THESE EVENTS, LONG TERM DOSING OF NOMLABOFUSP WAS GENERALLY WELL TOLERATED INCLUDING 8 PARTICIPANTS ON TREATMENT FOR OVER 1 YEAR ANAPHYLAXIS IS MORE COMMON UPON RE-EXPOSURE TO A DRUG AFTER A GAP IN DOSING; IN THE OL STUDY, OF THE 10 PARTICIPANTS WHO HAD NOT HAD PRIOR EXPOSURE TO NOMLABOFUSP ONLY 1 EXPERIENCED ANAPHYLAXIS (THIS REACTION WAS ONE OF THE 7 EVENTS DISCUSSED ABOVE). IMPLEMENTING A MODIFIED STARTING DOSE REGIMEN DESIGNED TO MITIGATE THE RISK OF ANAPHYLAXIS EVENTS AS AGREED TO BY THE FDA MODIFIED STARTING DOSE REGIMEN IS ALSO BEING INCORPORATED INTO THE PHASE 3 PROTOCOL; LARIMAR CONTINUES TO QUALIFY GLOBAL PHASE 3 SITES AND PREPARE FOR STUDY INITIATION AND PATIENT ENROLLMENT BLA SUBMISSION SEEKING ACCELERATED APPROVAL TARGETED IN THE SECOND QUARTER OF 2026 $175.4 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPTEMBER 30, 2025, WITH PROJECTED CASH RUNWAY INTO THE FOURTH QUARTER OF 2026 BALA CYNWYD, PA.

LARIMAR THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

NEW YORK , OCT. 28, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF LARIMAR THERAPEUTICS, INC. - LRMR

NEW YORK , OCT. 23, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , OCT. 18, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

LOS ANGELES , OCT. 16, 2025 /PRNEWSWIRE/ --THE DJS LAW GROUPANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC. ("LARIMAR" OR "THE COMPANY") (NASDAQ: LRMR) FOR VIOLATIONS OF THE SECURITIES LAWS. INVESTIGATION DETAILS: THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS.

LARIMAR THERAPEUTICS, INC. INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - LRMR

LOS ANGELES--(BUSINESS WIRE)--LARIMAR THERAPEUTICS, INC. INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  LRMR.

LARIMAR THERAPEUTICS, INC. INVESTIGATED FOR SECURITIES FRAUD VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  LRMR

NEW YORK , OCT. 13, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , OCT. 8, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OFLARIMAR THERAPEUTICS, INC.("LARIMAR" OR THE "COMPANY")(NASDAQ: LRMR).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

BALA CYNWYD, PA., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED POSITIVE 25 MG AND 50 MG DATA FROM THE ONGOING LONG-TERM OPEN LABEL (OL) STUDY EVALUATING DAILY SUBCUTANEOUS INJECTIONS OF NOMLABOFUSP SELF-ADMINISTERED OR ADMINISTERED BY A CAREGIVER IN PARTICIPANTS WITH FRIEDREICH'S ATAXIA (FA), A RARE, PROGRESSIVE, AND SYSTEMIC DISEASE WITH NEUROLOGIC DETERIORATION. THE COMPANY ALSO PROVIDED A NOMLABOFUSP DEVELOPMENT PROGRAM UPDATE.

LARIMAR THERAPEUTICS ANNOUNCES POSITIVE DATA FROM ONGOING LONG-TERM OPEN LABEL STUDY AND UPDATES TO NOMLABOFUSP PROGRAM FOR FRIEDREICH'S ATAXIA

CONFERENCE CALL AND WEBCAST ON MONDAY, SEPTEMBER 29, 2025 AT 8:00 AM EDT CONFERENCE CALL AND WEBCAST ON MONDAY, SEPTEMBER 29, 2025 AT 8:00 AM EDT

Larimar Therapeutics, Inc.

LRMR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Larimar Therapeutics, Inc.

LRMR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LRMR